These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22883365)

  • 41. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New meningococcal vaccines in the UK.
    Lloyd KE; Paul SP; Garg AK
    Community Pract; 2015 Nov; 88(11):28-30, 33. PubMed ID: 26749613
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meningococcal disease in travelers: update on vaccine options.
    Cramer JP; Wilder-Smith A
    Curr Opin Infect Dis; 2012 Oct; 25(5):507-17. PubMed ID: 22907278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Paediatric meningococcal meningitis in France: ACTIV/GPIP network results].
    Levy C; Taha MK; Bingen E; Cohen R;
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S49-54. PubMed ID: 22883366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(3):72-6. PubMed ID: 21270745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Acceptance of the new conjugate vaccines. Meningococcal and pneumococcal vaccines, in the cohort born in 1999, in the North Region of Portugal].
    De Queirós L; Castro L; Ferreira MC; Gonçalves G
    Acta Med Port; 2004; 17(1):49-53. PubMed ID: 15636727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neisseria meningitidis serogroup A vaccines: an overview.
    Vergnano S; Heath P
    Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
    Ostergaard L; Lebacq E; Poolman J; Maechler G; Boutriau D
    Vaccine; 2009 Jan; 27(1):161-8. PubMed ID: 18834910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; Erickson L
    Vaccine; 2002 Jun; 20(21-22):2840-4. PubMed ID: 12102036
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians.
    Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M
    Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meningococcal conjugate vaccine uptake, measured by Michigan's immunization registry.
    Enger KS; Stokley S
    J Adolesc Health; 2007 May; 40(5):398-404. PubMed ID: 17448396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reducing the dangers of pediatric pneumococcal disease with a new vaccine.
    Toth S; Davis RH; Donnelly RE; Leger MM; Muma RD; Taft JM
    JAAPA; 2001 Feb; 14(2):58-9. PubMed ID: 11523192
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.
    Black S; Klein NP; Shah J; Bedell L; Karsten A; Dull PM
    Vaccine; 2010 Jan; 28(3):657-63. PubMed ID: 19895922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.
    Alexander PG; Chartrand SA; Davies TJ; Gaines BM; Oster G; Shurin P; Tamsky L; Thornton DK; Wittert W
    Manag Care Interface; 2001; Suppl C():10-28; quiz 29-30. PubMed ID: 11724029
    [No Abstract]   [Full Text] [Related]  

  • 60. [Advances in vaccines and invasive disease in children].
    Moraga Llop FA
    Rev Esp Quimioter; 2001 Dec; 14(4):319-30. PubMed ID: 11856977
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.